WO2018154597A1

WO2018154597A1 - Process for synthesis of glycopyrronium bromide

Info

Publication number: WO2018154597A1
Application number: PCT/IN2018/050083
Authority: WO
Inventors: G. Nithun REDDY; G. Samhitha REDDY; G. Madaalasa REDDY; M Ramani; G. Pratap REDDY
Original assignee: GbR Laboratories Pvt Ltd; Rachana Pharma Tech
Current assignee: GbR Laboratories Pvt Ltd; Rachana Pharma Tech
Priority date: 2017-02-22
Filing date: 2018-02-19
Publication date: 2018-08-30
Anticipated expiration: 2019-08-22

Abstract

Provided herein are processes for preparation of glycopyrronium bromide comprising reaction of N-methylpyrrolidin-3-ol with compounds of Formula I or Formula II followed by additional steps.

Description

PROC E SS FOR SY NT H E SIS OF G LY COPY R RONIUM BROM IDE

This application claims priority to Indian Provisional Patent Application No. 201741006245 filed on 22 February 2017, which is incorporated herein in its entirety.

FIE L D OF INV E NTION This disclosure is related to a process for synthesis of glycopyrronium bromide.

BAC K G ROUND OF T H E INV E NTION

Glycopyrronium bromide (or glycopyrrolate) is a quaternary ammonium salt with the following chemical name: 3[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl pyrrolidinium bromide. The structural formula is shown below

The compound is an anticholinergic agent which is formulated for intramuscular or intravenous injection. Glycopyrronium bromide is indicated for use as a preoperative anti muscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and/or intubation. When indicated, it is used intraoperatively to counteract surgically or drug induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants.

There is a need in the art for efficient methods of synthesis of pharmaceutical grade glycopyrronium bromide. SUM MARY OF T H E INV E NTION

Provided herein are processes for preparation of glycopyrronium bromide comprising, in a first step, a reaction of N-methyl pyrrol idin-3-ol with a compound of Formula I or Formula II as described herein followed by a coupling reaction with a suitable organo- magnesium reagent as described herein.

DE TAIL E D DE SC RIPTION OF T H E INV E NTION

All materials used herein were commercially purchased as described herein or prepared from commercially purchased materials as described herein.

Previously known methods for synthesis of glycopyrronium bromide comprised a reaction of alpha-cycl openty I phenyl acetyl chloride with N-methyl pyrrol idin-3-ol. By contrast, described herein are processes wherein the synthesis of glycopyrronium bromide is achieved by initially coupling N-methyl pyrrol idin-3-ol with either 2-oxo-2-phenyl acetic acid derivatives or 2-oxo-2- cyclopentyl acetic acid derivatives followed by a Grignard reaction, as described in more detail i n the E xampl es secti on. In one aspect, provided herein is a process for preparation of glycopyrronium bromide comprising

(i) reacting N-methyl pyrrol i din- 3-ol with a compound of Formula I to obtain a compound of structure 3A:

Formula I

wherein X is H, OH, OMe or CI; and

( i i ) reacti ng the compound of structure 3A wi th phenyl magnesi urn bromi de to obtai n a compound of structure 5

3A

Scheme 1 describes certain non- limiting reaction conditions for the reaction of a compound of Formula I with N- methyl pyrrol i din- 3-ol. Other suitable coupling protocols will be apparent to one of ski 11 i n the art and are contempi ated wi thi n the scope of embodi ments descri bed herei n.

In one group of embodiments, said process further comprises reacting the compound of structure 5 with methyl bromide to obtain a compound of structure 6

In another aspect, provided herein is a process for preparation of glycopyrroni urn bromide comprising

(i) reacting N- methyl pyrrol i din- 3-ol with a compound of Formula II to obtain a compound of structure 3B:

Formula II to

wherein Y is H, OH, OMe or CI; and

(ii)reacting the compound of structure 3B with cyclopentyl magnesium chloride to obtain a compound of structure 5

Scheme 2 describes certain non- limiting reaction conditions for the reaction of a compound of Formula II with N-methylpyrrolidin-3-ol. Other suitable coupling protocols will be apparent to one of skill in the art and are contemplated within the scope of embodiments described herein. In one group of embodiments, the process described above further comprises reacting the compound of structure 5 with methyl bromide to obtain a compound of structure 6

EXA M PL E S EXAM PL E 1 Scheme 1

ST E P I

To a stirred solution of N-methyl pyrrol i din- 3-ol (2, 1 equiv) and Et₃N (1.2 equiv) in dichloromethane was added a solution of 2-cyclopentyl-2-oxoacetyl chloride (1, 1.1 equiv) in DCM at O °C under nitrogen atmosphere for 20 min. The resulting solution was allowed to stir at room temperature over 10h. After completion, the mixture was quenched with water and extracted with diethyl ether to afford the pure product (3A).

Similarly, the product 3A is also obtained by reaction of 2 with other reagents, phenyl oxalic acid, methyl phenyl oxalate, and phenyl hemi-oxaldehyde respectively as shown in Scheme 1.

ST E P II

3A To a mixture of bromobenzene (2.2 equiv) and Mg metal (2.2 equiv) in TH F (15 mL) was stirred over a period of 30 min at 0 · C. To this mixture, a solution of 1 -methyl pyrrol idin-3-yl 2- cyclopentyl-2-oxoacetate (3, 1 equiv) in T HF was added in portions over a period of 30 min. Up on completion, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was separated and concentrated in vacuo. The resulting residue was purified by column chromatography to afford the pure product (5).

ST E P III

To a solution of compound 5 (1 equiv) in acetonitrile and chloroform mixture (10 mL, 2:3) was added methyl bromide (4 equiv). The mixture was stirred at room temperature for 72h. The solvents were evaporated, and the resulting residue was washed with diethyl ether to afford the pure product (6) as a white solid.

EXAM PL E 2 Scheme 2 ST E P I

To a stirred solution of N-methyl pyrrol i din- 3-ol (2, 1 equiv) and Et₃N (1.2 equiv) in dichloromethane was added a solution of 2- oxo-2- phenyl acetyl chloride (1.1 equiv) in dichloromethane at 0 °C under nitrogen atmosphere for 15 min. The resulting solution was allowed to stir at room temperature over 12h. After completion, the mixture was quenched with water and extracted with diethyl ether to afford the pure product (3B).

Similarly, the product 3B is also obtained by reaction of 2 with other reagents, phenyl oxalic acid, methyl phenyl oxalate, and phenyl hemi-oxaldehyde respectively as shown in Scheme 2. ST E P II

To a mixture of cyclopentyl bromide (4, 2.2 equiv) and Mg metal (2.2 equiv) in THF (15 mL) was stirred over a period of 30 min at 0 - C. To this mixture, a solution of 1- methylpyrrolidin-3-yl-2-oxo-2-phenylacetate (3B, 1 equiv) in TH F was added in portions over a period of 30 min. Up on completion, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was separated and concentrated in vacuo. The resulting residue was purified by column chromatography to afford the pure product (5).

ST E P III

To a solution of compound 5 (1 equiv) in acetonitrile and chloroform mixture (10 mL, 2:3) was added methyl bromide (4 equiv). The mixture was stirred at room temperature for 75h. The solvents were evaporated, and the resulting residue was washed with diethyl ether to afford the pure product (6) as a white solid.

The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated by those skilled in the art that changes may be made in these embodiments without departing from the principles and nature of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims

C laims :

1. A process for preparati on of gl ycopy rroni um bromi de compri si ng

(i) reacting N-methyl pyrrol idin-3-ol with a compound of Formula I to obtain a compound of structure 3A:

Formula I t5

wherein X is H, OH, OMe or CI; and

( i i ) reacti ng the compound of structure 3A wi th phenyl magnesi um bromi de to obtai n a compound of structure 5

3A

2. T he process of clai m 1 , further comprisi ng reacti ng the compound of structure 5 with methyl bromide to obtain a compound of structure 6

3. A process for preparati on of gl ycopy rroni um bromi de compri si ng

(i) reacting N-methyl pyrrol idin-3-ol with a compound of Formula II to obtain a compound of structure 3B:

Formula II to

wherein Y is H, OH, OMe or CI; and

(ii)reacting the compound of structure 3B with cyclopentyl magnesium chloride to obtain a com ound of structure 5

4. T he process of clai m 3, further comprisi ng reacti ng the compound of structure 5 with